American technology firm donates funds to JDRF and American Diabetes Association

An American medical device company called Insulet Corporation has donated $10,000 (£7,000) each to the Juvenile Diabetes Research Foundation (JDRF) and the American Diabetes Association (ADA).
Insulet, based in Billerican, Massachusetts, raised the funds following a company-sponsored three-day initiative in which thousands of US clinicians wore a demo of the OmniPod system.
OmniPod is a discreet and unique insulin delivery system which can calculate suggested doses and administer insulin without the hassle of tubes. It can provide up to three days of non-stop insulin delivery, has a built-in blood glucose meter, and because it is waterproof it does not have to be removed when showering or swimming. The device is available to purchase online in the UK.
“Our mission is to improve the lives of individuals living with diabetes,” said Patrick Sulliva, President and Chief Executive Officer of Insulet. “The successful fundraising efforts by the employees of Insulet underscore their creativity, dedication and commitment to this very important cause.”
The funds were raised as part of November’s National Diabetes Awareness, and Insulet donated to either the ADA or the JDRF for each clinician who participated in the program.
The JDRF is a leading global funder of type 1 diabetes research that has international affiliates in the UK, Australia, and several European countries. It hosts several fundraising events every year across the UK.
Margo K. Lucero, Senior Vice President, Corporate and International Development of JDRF said: “We graciously accept this donation from Insulet and its employees who share our desire to not only research for tomorrow, but find the best possible diabetes treatments for today.”
Jonathan Webb, Vice President, Corporate Alliances and Grants, American Diabetes Associatio, added: “[This donation] will help advance our cutting-edge research efforts aimed to prevent, cure and manage all types of diabetes.
“But as we celebrate advances, we also promise to never let down our guard in both the fight against diabetes and the fight for all people affected by diabetes.”